Xueqin Gong

Xueqin Gong

Auto-generated profile, based on publicly available information

Xueqin Gong

Department of Radiology, Chongqing University Cancer Hospital, Chongqing Key Laboratory for Intelligent Oncology in Breast Cancer, No. 181 Hanyu Rd, Shapingba District, Chongqing 400030, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in Radiology
Verified
Journal Article
Closed access
YHYao Huang
Yao Huang
XWXiaoxia Wang
Xiaoxia Wang
YCYing Cao
Ying Cao
XLXiaosong Lan
Xiaosong Lan
XHXiaofei Hu
Xiaofei Hu
JZJiuquan Zhang
Jiuquan Zhang
A nomogram model combining intratumoral heterogeneity score and clinicopathologic variables predicted pathologic complete response to neoadjuvant chemotherapy well, and nomogram scores were associated with recurrence-free survival and biologic pathways.

1 July 2025 in Radiology
Verified
Journal Article
Closed access
XGXueqin Gong
Xueqin Gong
XWXiaoxia Wang
Xiaoxia Wang
LWLu Wang
Lu Wang
XZXiangfei Zeng
Xiangfei Zeng
STSun Tang
Sun Tang
JZJiuquan Zhang
Jiuquan Zhang
A model combining clinicopathologic variables and diffusion kurtosis imaging parameters after two cycles of neoadjuvant chemotherapy demonstrated excellent performance in predicting pathologic complete response in participants with breast cancer.

1 March 2025 in Radiology: Imaging Cancer
Verified
Journal Article
Closed access
HCHuifang Chen
Huifang Chen
XWXiaoxia Wang
Xiaoxia Wang
YHYao Huang
Yao Huang
YCYing Cao
Ying Cao
MCMeimei Cao
Meimei Cao
JZJiuquan Zhang
Jiuquan Zhang
Three nomogram models combining apparent diffusion coefficient and clinicopathologic features showed good performance in predicting status of pretreatment axillary lymph nodes, nonsentinel lymph nodes, and the axillary lymph nodes after neoadjuvant chemotherapy treatment in patients with breast cancer.

8 September 2021 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
XGXue-Qin Gong
Xue-Qin Gong
YTYun-Yun Tao
Yun-Yun Tao
RWRan Wang
Ran Wang
NLNian Liu
Nian Liu
XHXiao-Hua Huang
Xiao-Hua Huang
XZXiaoming Zhang
Xiaoming Zhang
Background: Bone metastasis is one of the most common complications of Prostate Cancer (PCa). The detection of distal bone metastasis at the time of initial PCa diagnosis is valuable for the determination of therapeutic methods and for the prognosis of PCa. Many current therapeutic methods target PCa bone metastasis, but no uniform evaluation standard for therapeutic efficacy has been established; in addition, traditional therapeutic evaluation standards that rely on changes in the measured tumor volume are quite controversial. In clinical practice, the volumes of some tumors often change nonsignificantly at the early stage of therapy (especially targeted therapy), while the volumes of other tumors, such as metastatic bone lesions, are difficult to measure. Diffusion-Weighted Imaging (DWI) not only reflects the diffusion characteristics of tissues but can also allow the analysis of microstructural and functional changes in tissues. Therefore, DWI is suitable for evaluations of early responses to tumor therapy. Objective: This study mainly reviews the principle of DWI and its progress in the detection and therapy evaluation of PCa bone metastasis. Methods: PubMed was searched to identify eligible articles up to December 26, 2020. The keywords of the analysis included DWI, PCa, bone metastasis, therapeutic response, targeted therapy, Bone Scintigraphy (BS), Positron Emission Tomography/Computed Tomography (PET/CT) and metastatic Castration-Resistant Prostate Cancer (mCRPC). Results: This review based on collected articles achieved an imaging biomarker for detection and therapy evaluation of PCa bone metastasis. Conclusion : DWI is a promising imaging method for the detection and therapeutic evaluation of PCa bone metastases.